Acta medica (Hradec Kralove) 2003
Response to gefitinib in pericardial effusion due to lung cancer.
Apenas usuários registrados podem traduzir artigos
Entrar Inscrever-se
O link é salvo na área de transferência
Palavras-chave
Resumo
We described a 70 years old patient with pericardial effusion due to adenocarcinoma of the lung, in whom gefitinib, which is an oral selective inhibitor of the epidermal growth factor receptor of tyrosine kinase, demonstrated a marked antitumor effect. We recommend possible consideration of a treatment with gefitinib for female patients with pericarditis carcinomatosa due to lung adenocarcinoma, even if they have a poor performance status and are not indicated for other intensive therapy.